Agfa-Gevaert NV

DB:AGE Stock Report

Market Cap: €103.7m

Agfa-Gevaert Valuation

Is AGE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AGE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AGE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AGE's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AGE?

Key metric: As AGE is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for AGE. This is calculated by dividing AGE's market cap by their current revenue.
What is AGE's PS Ratio?
PS Ratio0.09x
Sales€1.13b
Market Cap€103.73m

Price to Sales Ratio vs Peers

How does AGE's PS Ratio compare to its peers?

The above table shows the PS ratio for AGE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.1x
AJ91 DocCheck
0.8xn/a€42.1m
M3V MeVis Medical Solutions
2.6xn/a€45.1m
COP CompuGroup Medical SE KGaA
0.6x1.4%€726.9m
NXU Nexus
4.5x9.8%€1.2b
AGE Agfa-Gevaert
0.09x4.6%€103.7m

Price-To-Sales vs Peers: AGE is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (2.1x).

Price to Sales Ratio vs Industry

How does AGE's PS Ratio compare vs other companies in the European Healthcare Services Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.2.2x8.5%
AGE Agfa-Gevaert
 0.09x4.6%US$108.02m
AGE 0.1xIndustry Avg. 2.2xNo. of Companies11PS02.44.87.29.612+
6 CompaniesEstimated GrowthMarket Cap
Industry Avg.2.2x29.7%
AGE Agfa-Gevaert
 0.09x113.3%US$108.02m
No more companies

Price-To-Sales vs Industry: AGE is good value based on its Price-To-Sales Ratio (0.1x) compared to the European Healthcare Services industry average (2.2x).

Price to Sales Ratio vs Fair Ratio

What is AGE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AGE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.09x
Fair PS Ratio0.5x

Price-To-Sales vs Fair Ratio: AGE is good value based on its Price-To-Sales Ratio (0.1x) compared to the estimated Fair Price-To-Sales Ratio (0.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AGE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.65
€1.33
+104.8%
7.1%€1.40€1.20n/a3
Nov ’25€0.96
€1.53
+59.9%
22.2%€2.00€1.20n/a3
Oct ’25€1.06
€1.60
+50.4%
25.0%€2.00€1.20n/a2
Sep ’25€1.14
€1.80
+57.3%
11.1%€2.00€1.60n/a2
Aug ’25€1.18
€1.83
+55.9%
9.3%€2.00€1.60n/a3
Jul ’25€1.12
€1.83
+64.0%
9.3%€2.00€1.60n/a3
Jun ’25€1.18
€1.83
+55.6%
9.3%€2.00€1.60n/a3
May ’25€1.20
€1.83
+52.8%
9.3%€2.00€1.60n/a3
Apr ’25€1.31
€1.83
+39.9%
9.3%€2.00€1.60n/a3
Mar ’25€1.04
€1.83
+77.0%
9.3%€2.00€1.60n/a3
Feb ’25€1.24
€1.80
+45.6%
11.1%€2.00€1.60n/a2
Jan ’25€1.45
€2.30
+58.6%
30.4%€3.00€1.60n/a2
Nov ’24€1.52
€3.63
+139.3%
17.5%€4.50€3.00€0.963
Oct ’24€1.83
€3.63
+98.1%
17.5%€4.50€3.00€1.063
Sep ’24€2.10
€3.63
+73.4%
17.5%€4.50€3.00€1.143
Aug ’24€2.33
€3.75
+60.9%
20.0%€4.50€3.00€1.182
Jul ’24€2.22
€3.75
+68.9%
20.0%€4.50€3.00€1.122
Jun ’24€2.46
€3.75
+52.4%
20.0%€4.50€3.00€1.182
Dec ’23€2.80
€4.45
+58.9%
10.1%€4.90€4.00€1.382
Nov ’23€3.03
€4.45
+46.9%
10.1%€4.90€4.00€1.522

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

LNA Santé

€244.4m

Engages in the management and operation of health establishments.

2N3

€23.25

7D

-5.5%

1Y

18.9%

Shandong Weigao Group Medical Polymer

HK$20.1b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

7D

-8.8%

1Y

-37.3%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%